Trastuzumab: Anti-HER2 antibody for treatment of metastatic breast cancer

被引：13
|
作者：
Wong, WM [1 ]
机构：
[1] Univ Calif Irvine, Med Ctr, Pharmaceut Serv, Orange, CA 92717 USA
来源：
CANCER PRACTICE | 1999年 / 7卷 / 01期
关键词：
D O I：
10.1046/j.1523-5394.1999.07108.x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：48 / 50
页数：3
相关论文
共 50 条
  • [1] Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer
    Albanell, J
    Baselga, J
    [J]. DRUGS OF TODAY, 1999, 35 (12): : 931 - 946
  • [2] Treatment with combinations of the Anti-HER2 antibody trastuzumab and capecitabine in advanced metastatic breast cancer patients - a pilot study
    Braun, Michael
    Schlehe, Bettina
    Faricli, Andree
    Heindrichs, Uwe
    Rudlowski, Christian
    [J]. BREAST CARE, 2007, 2 (04) : 227 - 233
  • [3] Use of the monoclonal antibody Anti-HER2 trastuzumab in the treatment of metastatic breast cancer - A cost-effectiveness analysis
    Poncet, Benedicte
    Bachelot, Thomas
    Colin, Cyrille
    Ganne, Christell
    Jaisson-Hot, Isahelle
    Uvre, Hithert -F
    Peaud, Pierre-Yves
    Jacquin, Jean-Philippe
    Salles, Bruno
    Tigaud, Jean-Donfinique
    Mechin-Cretinon, Aabelle
    Marechal, Francois
    Fournel, Cecile
    Lenoir, Veronique Trillet
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (04): : 363 - 368
  • [4] Use of the monoclonal antibody anti-HER2 (Trastuzumab, HERCEPTIN®) in the treatment of metastatic breast cancer: medical and economical evaluation
    Lenoir, Veronique Trillet
    Poncet, Benedicte
    Ganne, Christell
    Heilmann, Marie-Odile
    Hajri, Touria
    Jaisson-Hot, Isabelle
    Freyer, Gilles
    Colin, Cyrille
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 38 - 38
  • [5] Pathological evaluation of HER2 overexpression: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab)
    Umemura, S
    Sekido, Y
    Itoh, H
    Osamura, RY
    [J]. ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (02) : 77 - 81
  • [6] Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
    Shak, S
    [J]. SEMINARS IN ONCOLOGY, 1999, 26 (04) : 71 - 77
  • [7] Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)
    Shinobu Umemura
    Goi Sakamoto
    Hironobu Sasano
    Hitoshi Tsuda
    Futoshi Akiyama
    Masafumi Kurosumi
    Yutaka Tokuda
    Toru Watanabe
    Masakazu Toi
    Tadashi Hasegawa
    R. Yoshiyuki Osamura
    [J]. Breast Cancer, 2001, 8 (4) : 316 - 320
  • [8] Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
    Vazquez-Martin, Alejandro
    Oliveras-Ferraros, Cristina
    Menendez, Javier A.
    [J]. PLOS ONE, 2009, 4 (07):
  • [9] Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan
    Yutaka Tokuda
    Yasuhiro Suzuki
    Masatoshi Ohta
    Yuki Saito
    Mitsuhiro Kubota
    Tomoo Tajima
    Shinobu Umemura
    R. Yoshiyuki Osamura
    [J]. Breast Cancer, 2001, 8 (4) : 310 - 315
  • [10] Advances in anti-HER2 therapy in metastatic breast cancer
    Yao, Minya
    Fu, Peifen
    [J]. CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
12345